2025
Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis
Sumsuzzman D, Ye Y, Wang Z, Pandey A, Langley J, Galvani A, Moghadas S. Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis. BMC Infectious Diseases 2025, 25: 215. PMID: 39948450, PMCID: PMC11827239, DOI: 10.1186/s12879-025-10610-5.Peer-Reviewed Original ResearchConceptsPopulation settingEffective public health strategiesConfidence intervalsImpact of disease severityModified Newcastle-Ottawa ScalePublic health strategiesHigher secondary attack rateRisk of biasNewcastle-Ottawa ScalePandemic responseGlobal systematic reviewRandom-effects modelFreeman-Tukey double arcsine transformationWeb of ScienceNo significant associationDrivers of SARS-CoV-2 transmissionHealth strategiesSecondary attack rateSARS-CoV-2Disease severityEffective pandemic responseTargeted interventionsDouble arcsine transformationOvid MEDLINESystematic reviewImpact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Du Z, Pandey A, Moghadas S, Bai Y, Wang L, Matrajt L, Singer B, Galvani A. Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults. Nature Medicine 2025, 31: 647-652. PMID: 39789324, PMCID: PMC11835734, DOI: 10.1038/s41591-024-03431-7.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSyncytial virusRSV diseaseImpact of vaccinationBurden of respiratory syncytial virusVaccination of pregnant womenRSV-related mortalityProtein-based vaccinesVaccination of older adultsRSV vaccinePregnant womenSeasonal influenzaVaccine uptake ratesInfant hospitalizationClinical trialsPrefusion FHospital costsInfantsHealth burdenAdult immunizationVaccineOlder adultsHospitalEnhanced uptakeHigh-income countries
2024
Mortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States
Pandey A, Fitzpatrick M, Singer B, Galvani A. Mortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321494121. PMID: 38648491, PMCID: PMC11066981, DOI: 10.1073/pnas.2321494121.Peer-Reviewed Original ResearchA retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Du Z, Wang L, Bai Y, Liu Y, Lau E, Galvani A, Krug R, Cowling B, Meyers L. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. ELife 2024, 13: e89801. PMID: 38622989, PMCID: PMC11078542, DOI: 10.7554/elife.89801.Peer-Reviewed Original ResearchConceptsViral sheddingHospitalized COVID-19 patientsSARS-CoV-2Retrospective cohort studyRisk of reboundCOVID-19 patientsViral reboundTime of treatmentTreated patientsPreventing severe illnessEarly treatmentCohort studyHospitalized patientsPatientsViral replicationReducing infectiousnessSevere illnessTimely treatmentViral dynamicsHealth record dataTreatmentTransmission riskTransmission of SARS-CoV-2EfficacySymptoms
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use
2009
Optimizing Influenza Vaccine Distribution
Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. Science 2009, 325: 1705-1708. PMID: 19696313, DOI: 10.1126/science.1175570.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedCenters for Disease Control and Prevention, U.S.ChildChild, PreschoolDisease OutbreaksHealth PolicyHumansImmunization ProgramsInfantInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInfluenza, HumanMiddle AgedModels, StatisticalUnited StatesVaccinationYoung AdultConceptsOutcome measuresNovel swine-origin influenzaOptimal vaccine allocationInfluenza vaccine distributionContingent valuationSwine-origin influenzaYears of lifePublic health policyOptimal allocationEconomic costsInfluenza vaccineSeasonal influenzaInfluenza pandemicU.S. CentersVaccine allocationDisease controlMortality dataVaccine distributionHealth policyOptimal vaccinationPolicy optimizationTransmission dynamicsInfluenzaAllocationNew recommendations
2007
Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum
Galvani AP, Reluga TC, Chapman GB. Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 5692-5697. PMID: 17369367, PMCID: PMC1838447, DOI: 10.1073/pnas.0606774104.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationInfluenza vaccination policiesVaccine allocation strategiesEpidemic influenzaPandemic influenzaInfluenza mortalityVaccination levelsVaccination programVaccination strategiesVaccination policyInfluenza transmissionVaccinationGreater riskDisease controlInfluenzaMortalityChildrenQuestionnaire dataMorbidityVaccine
2003
Evaluating plague and smallpox as historical selective pressures for the CCR5-Δ32 HIV-resistance allele
Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Δ32 HIV-resistance allele. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 15276-15279. PMID: 14645720, PMCID: PMC299980, DOI: 10.1073/pnas.2435085100.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply